Despite recent advances in the treatment of some forms of leishmaniasis, the
available drugs are still far from ideal due to inefficacy, parasite resistance,
toxicity and cost. The wide-spectrum antimicrobial activity of 2-nitrovinylfuran
compounds has been described, as has their activity against Trichomonas vaginalis and
other protozoa. Thus, the aim of this study was to test the antileishmanial
activities of six 2-nitrovinylfurans in vitro and in a murine model of leishmaniasis.
Minimum parasiticide concentration (MPC) and 50% inhibitory concentration
(IC50) values for these compounds against the promastigotes of
Leishmania amazonensis, Leishmania infantum and Leishmania braziliensis were
determined, as were the efficacies of two selected compounds in an experimental model
of cutaneous leishmaniasis (CL) caused by L. amazonensis in BALB/c mice. All of the
compounds were active against the promastigotes of the three Leishmania species
tested. IC50 and MPC values were in the ranges of 0.8-4.7 µM and 1.7-32
µM, respectively. The compounds 2-bromo-5-(2-bromo-2-nitrovinyl)-furan (furvina) and
2-bromo-5-(2-methyl-2-nitrovinyl)-furan (UC245) also reduced lesion growth in vivo at
a magnitude comparable to or higher than that achieved by amphotericin B treatment.
The results demonstrate the potential of this class of compounds as antileishmanial
agents and support the clinical testing of Dermofural(r) (a
furvina-containing antifungal ointment) for the treatment of CL.